Click on the links below to see other publications about riociguat for the treatment of PAH, the 2015 ESC/ERS PAH treatment guidelines, and the US and EU prescribing information
-
REPLACE primary manuscript
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial -
REPLACE primary data presented at ERS 2020
REPLACE primary data presented at ERS 2020 -
RESPITE primary
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
Hoeper MM et al. Eur Respir J 2017 -
PATENT-1
Riociguat for the treatment of pulmonary arterial hypertension
Ghofrani HA et al. N Engl J Med 2013 -
RESPITE secondary
Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE
Benza RL et al. Int J Cardiol 2020 -
PATENT-2 1-year
Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).
Rubin LJ et al. Eur Respir J 2015 -
PATENT-2 2-year
Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension; data from the PATENT-2 open-label, randomised, long-term extension trial
Ghofrani HA et al. Lancet Respir Med 2016 -
PATENT hemodynamics
Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study
Galiè N et al. J Heart Lung Transplant 2017 -
PATENT PAH-CTD
Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2
Humbert M et al. Ann Rheum Dis 2017 -
PATENT PAH-CHD
Riociguat for pulmonary arterial hypertension associated with congenital heart disease
Rosenkranz S et al. Heart 2015 -
PATENT PoPH
Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies
Cartin-Ceba R et al. Pulm Circ 2018 -
RESPITE study design
Rationale and study design of RESPITE: an open-label phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors
Hoeper MM et al. Respir Med 2017 -
ESC/ERS 2015 pulmonary hypertension treatment guidelines
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)
Galiè N et al. Eur Respir J 2015 -
Adempas US prescribing information
Bayer AG -
Adempas EU summary of product characteristics
Bayer AG